← Back to Search

Dermabond for Ascites-related Fluid Leaks

N/A
Waitlist Available
Led By Ahmed Alobaidi, MD
Research Sponsored by Methodist Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial found that 2-Octyl cyanoacrylate (2-OCA) is an effective treatment for fluid leaks following paracentesis.

Who is the study for?
This trial is for adult inpatients at Methodist Dallas Medical Center with ascites needing bedside therapeutic paracentesis. It's not for those who had liver or abdominal surgery within 48 hours, procedures done outside the procedure team, or using devices other than the 18 gauge Safe-T-Centesis kit.Check my eligibility
What is being tested?
The trial tests Dermabond (2-Octyl cyanoacrylate), a skin adhesive used to seal wounds, to see if it can prevent fluid leaks after paracentesis—a common issue when draining excess fluid from the abdomen of patients with ascites.See study design
What are the potential side effects?
While specific side effects are not listed here, similar skin adhesives have been known to cause skin irritation, allergic reactions, and rarely infection at the application site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Access post-paracentesis fluid leaks
Access the rate of complications
Access topical 2-OCA application
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Glue Group (GG)Experimental Treatment1 Intervention
Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
Group II: No Glue Group (NG)Active Control1 Intervention
Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.

Find a Location

Who is running the clinical trial?

Methodist Health SystemLead Sponsor
145 Previous Clinical Trials
4,824,170 Total Patients Enrolled
Ahmed Alobaidi, MDPrincipal InvestigatorMethodist Health System

Media Library

Dermabond Clinical Trial Eligibility Overview. Trial Name: NCT05278013 — N/A
Ascites Research Study Groups: Glue Group (GG), No Glue Group (NG)
Ascites Clinical Trial 2023: Dermabond Highlights & Side Effects. Trial Name: NCT05278013 — N/A
Dermabond 2023 Treatment Timeline for Medical Study. Trial Name: NCT05278013 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible for me to become involved in this clinical trial?

"This clinical trial is accepting 134 patients aged between 18 and 100 who suffer from ascites. The study necessitates that the participants be admitted to Methodist Dallas Medical Centre, where their paracentesis will be done in-house by a specialist bedside procedure team."

Answered by AI

Does this experiment still welcome participants?

"According to clinicaltrials.gov, the registration period for this trial has closed; it was initially posted on January 13th 2022 and last updated October 21st of the same year. Despite this, 35 other medical trials are presently recruiting patients."

Answered by AI

Is the age criterion for this clinical trial restricted to individuals younger than 35 years old?

"To qualify for participation in this clinical trial, prospective subjects must be between 18 and 100 years old. Furthermore, there is one study specifically dedicated to those under the age of 18 while 33 studies are available for seniors above 65."

Answered by AI
~42 spots leftby Mar 2025